RxDoctor Payments DataLook up a doctor →

Natalia Kayloe, MD

Neurology · Falls Church, VANPI 1497745913

Payments from drug & device makers

$209,385in general payments, 2019–2025

Across 1,653 payments — averaging $126.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$105K
  • Eli Lilly$39K
  • Biohaven Pharmaceuticals, Inc.$12K
  • Axsome Therapeutics, Inc.$11K
  • Biohaven Pharmaceutical Holding Company Ltd.$8K
  • Pfizer$7K
  • plus $28K from 54 others
$4,263in research payments, 2019–2025

Across 2 payments — averaging $2131.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$4K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)453$104,878
Eli Lilly4$38,889
Biohaven Pharmaceuticals, Inc.41$11,513
Axsome Therapeutics, Inc.24$10,911
Biohaven Pharmaceutical Holding Company Ltd.24$7,670
Pfizer63$7,168
Novartis109$2,993
Lundbeck LLC65$2,694
Lilly USA, LLC112$2,484
Amgen(2 entities)56$2,108
Biogen56$1,670
EMD Serono, Inc.28$1,554
Upsher-smith Laboratories LLC23$1,554
Teva Pharmaceuticals USA, Inc.72$1,273
UCB, Inc.56$1,237
Sunovion Pharmaceuticals Inc.47$899
Neurocrine Biosciences, Inc.28$761
Eisai Inc.34$692
Harmony Biosciences LLC24$656
Supernus Pharmaceuticals, Inc.33$625
Neurelis, Inc.19$432
TG Therapeutics, Inc.4$415
Neuronetics, Inc.2$393
Bristol Myers Squibb19$336
E.r. Squibb & Sons, L.L.C.11$322
Jazz Pharmaceuticals Inc.18$304
AstraZeneca5$300
Amneal Pharmaceuticals LLC15$299
Avanir Pharmaceuticals, Inc.20$294
Impel Pharmaceuticals Inc.9$270
Arbor Pharmaceuticals, Inc.13$248
Sumitomo Pharma America, Inc.12$234
Medtronic2$218
MDD US Operations, LLC10$178
Sanofi8$170
Corium, LLC11$165
Merz Pharmaceuticals, LLC6$161
Assertio Therapeutics, Inc.7$148
Otsuka America Pharmaceutical, Inc.8$147
GE HealthCare5$146
Currax Pharmaceuticals LLC10$145
Merz North America, Inc.3$138
Kyowa Kirin, Inc.7$129
Averitas Pharma Inc.2$123
Azurity Pharmaceuticals, Inc.6$122
Genentech USA, Inc.8$122
Adamas Pharmaceuticals, Inc.6$116
Scilex Pharmaceuticals Inc.6$116
Collegium Pharmaceutical, Inc.6$111
Revance Therapeutics, Inc.2$78
Idorsia Pharmaceuticals US Inc5$76
Livanova USA, Inc.4$74
Johnson & Johnson3$71
Acorda Therapeutics, Inc4$70
Boston Scientific2$62
Avadel CNS Pharmaceuticals, LLC3$50
Takeda Pharmaceuticals U.S.A., Inc.2$43
Life Molecular Imaging Ltd3$42
Argenx US, Inc.2$33
SK Life Science, Inc.1$32

How this compares

$209,385 in reported general payments places this provider in the 90th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia →

Medicare billing

Part B allowed, 2024
$349,131
Medicare patients
1,061
Services billed
15,975

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Falls Church

See the full list for Virginia →

Where these figures come from

Is this you, or does something look wrong? →